Wegovy Pill Real-World Data Shows 6% Weight Loss in 3 Months, Supporting Oral Franchise

What happened

Novo Nordisk's Wegovy pill demonstrated approximately 6% weight loss after three months in real-world use, according to new data reported by Reuters. This real-world evidence corroborates the pill's efficacy seen in clinical trials and reinforces the commercial traction of oral semaglutide, which has already generated DKK 10.9 billion in sales during the first nine months of 2026. The data also come as Novo holds about 80% US new-to-brand share in oral obesity, underscoring strong patient demand despite competitive inroads from Eli Lilly's Foundayo. However, the stock continues to face significant headwinds from the scheduled January 2027 US price reset to $675 and intensifying price competition, which have dominated investor concerns. While this efficacy data is a positive signal for patient retention and payer negotiations, it does not directly address the core challenges of pricing pressure and market share defense that currently define the investment thesis for NVO.

Implication

The 6% weight loss observed in real-world use confirms the clinical benefit of the Wegovy pill, which could improve patient adherence and strengthen Novo's case for reimbursement in ongoing payer discussions. This may help sustain growth in the oral obesity category and defend against Lilly's Foundayo, which has already captured over 30% of new US oral patients. However, the scheduled January 2027 price reset to $675 and Medicare price cuts still threaten realized net pricing, and volume growth must accelerate to offset these declines. Investors should monitor whether the pill's real-world efficacy translates into sustained market share gains and prescription volume growth, particularly after the price reset takes effect. The news is mildly positive but insufficient to change the stock's near-term outlook without evidence that the pricing pressure can be absorbed through higher volumes or that upcoming launches like CagriSema provide a clear replacement growth engine.

Thesis delta

The investment thesis remains a potential buy with cautious view; the real-world efficacy data adds a small positive evidence point supporting oral semaglutide's real-world performance. However, the core concerns about locked-in pricing pressure and intensifying competition from Eli Lilly are unchanged, so there is no material shift in conviction. The thesis continues to hinge on whether oral volumes can offset the 2027 price reset and whether CagriSema can successfully launch to extend the obesity franchise beyond semaglutide.